Heilbronn L K, Noakes M, Morris A M, Kind K L, Clifton P M
Department of Physiology, University of Adelaide, PO Box 10041, Adelaide, S.A. Australia.
Atherosclerosis. 2000 May;150(1):187-92. doi: 10.1016/s0021-9150(99)00367-6.
Obesity is commonly associated with high rates of cardiovascular disease (CVD). Weight loss in obese subjects reduces risk factors for CVD but this response is not uniform. Genetic factors could be involved in this variability. The 360His polymorphism of apolipoproteinA-IV (apoA-IV) influences the lipid response to fat intake, but it is unclear whether this polymorphism could contribute to lipid variability during weight loss. Therefore, we assessed the effects of an energy restricted diet (6.3 MJ) for 12 weeks on weight loss and plasma lipids according to apoA-IV genotype in 186 overweight/obese subjects (BMI mean 33+/-4.3, range 25.0-48.0 kg/m(2)). The frequency of the 360His allele was 0.083. Energy restriction for 12 weeks resulted in an average weight loss of 8. 25+/-0.28 kg. HDL-C increased 5.4% in subjects with the apoA-IV-1/1 genotype with weight loss compared to a 2.6% decrease in apoA-IV-1/2 subjects (P=0.035). This was more apparent when only the subjects with type 2 diabetes (n=57) were analyzed (P=0.003). ApoA-IV genotype was not related to change in total cholesterol, LDL-C or triglyceride concentrations. Therefore, weight loss as a treatment to reduce CVD risk factors may be more effective in subjects with the apoA-IV-1/1 variant as compared to those with the apoA-IV-1/2 variant, especially in subjects with type 2 diabetes.
肥胖通常与心血管疾病(CVD)的高发病率相关。肥胖受试者体重减轻可降低CVD的危险因素,但这种反应并不一致。遗传因素可能与这种变异性有关。载脂蛋白A-IV(apoA-IV)的360His多态性会影响脂质对脂肪摄入的反应,但尚不清楚这种多态性是否会导致体重减轻期间的脂质变异性。因此,我们根据apoA-IV基因型评估了186名超重/肥胖受试者(BMI平均为33±4.3,范围为25.0 - 48.0 kg/m²)进行为期12周的能量限制饮食(6.3 MJ)对体重减轻和血浆脂质的影响。360His等位基因的频率为0.083。12周的能量限制导致平均体重减轻8.25±0.28 kg。与apoA-IV-1/2受试者体重减轻时HDL-C下降2.6%相比,apoA-IV-1/1基因型受试者的HDL-C增加了5.4%(P = 0.035)。仅分析2型糖尿病受试者(n = 57)时,这种差异更明显(P = 0.003)。apoA-IV基因型与总胆固醇、LDL-C或甘油三酯浓度的变化无关。因此,作为降低CVD危险因素的一种治疗方法,与apoA-IV-1/2变异型受试者相比,apoA-IV-1/1变异型受试者体重减轻可能更有效,尤其是在2型糖尿病受试者中。